Home › Heart Failure › Missouri › Kansas City
Heart Failure clinical trials in Kansas City, MO
25 studies for Heart Failure are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ELEVATE-HFpEF Clinical Study
Recruiting
- Saint Lukes Mid America Heart Institute, Kansas City
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
RecruitingPhase 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RecruitingPhase 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · 2 mi away
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RecruitingPhase 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
RecruitingPhase 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RecruitingPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Recruiting
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
RecruitingPhase 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RecruitingPhase 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
RecruitingPhase 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
RecruitingObservational study
- St. Luke's Hospital of Kansas City, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
RecruitingPhase 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RecruitingObservational study
- Kansas City, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecruitingObservational study
- St. Luke's Mid-America Heart Institute, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
RecruitingPhase 3
- Tenax Investigational Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
RecruitingPhase 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
Recruiting
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
RecruitingPhase 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Recruiting
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
RecruitingObservational study
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
RecruitingObservational study
- Saint Luke's Health System, Kansas City
About Heart Failure
Heart failure, or congestive heart failure (CHF), means the heart can't pump enough blood. Learn about the signs, symptoms, and causes.
More about Heart Failure on MedlinePlus
Heart Failure trials in other cities
- New York City, NY51 studies
- Boston, MA44 studies
- Dallas, TX42 studies
- Houston, TX36 studies
- Cleveland, OH33 studies
- Chicago, IL31 studies
- Philadelphia, PA31 studies
- San Francisco, CA29 studies
- Durham, NC26 studies
- St. Louis, MO26 studies
- Atlanta, GA25 studies
- Cincinnati, OH24 studies
Other studies in Kansas City
- Breast Cancer34 studies
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)21 studies
- Lung Cancer19 studies
- Colorectal Cancer16 studies
- Metastatic Cancer15 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer14 studies
- Ovarian Cancer11 studies
- Obesity11 studies
- Type 2 Diabetes11 studies
- Cardiovascular Disease11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.